Published research overview

How clinical research is distributed

This analysis computes activity and mapping coverage from CureCurrent's current published clinical-trial projection. It is not an estimate of worldwide disease prevalence, treatment efficacy, or all trials registered anywhere.

Investigate these findings

Compare research activityChoose two diseases, RxNorm drug concepts or sponsor portfolios and examine how their registered research differs. Visual evidence explorerFollow source-backed drug, disease, sponsor and trial relationships without confusing co-occurrence with clinical proof. Original research briefsLearn where mapped research activity, sponsors and terminology gaps are concentrated in this published snapshot.
Published studies134,886Distinct currently published NCT records
Recruiting studies14,44010.7% of published trials · registry-reported status
Drug intervention mapping36.6%40,758 of 111,416 registered drug intervention rows link to an RxNorm concept
Condition mapping47.2%127,362 of 269,582 raw study condition rows link to a disease concept

Longitudinal research tracking

CureCurrent can record daily snapshots of published trial counts and recruiting statuses. The historical trend appears after at least two separately captured days; no missing dates are fabricated or backfilled from current study statuses. The start-year chart below is a separate view of registered study start dates.

Find a disease, drug, or sponsor in the underlying research

Choose a suggestion to identify the exact registry record; clicking Explore Evidence opens its source-backed connections.

Research patterns in the published data

These graphics distinguish trial activity, reported recruiting status, geographic concentration and source-identity coverage. Bar lengths represent published record counts, not effectiveness or disease prevalence.

Trial starts in the last 10 calendar yearsRegistered start year; turquoise is the subset reported as recruiting in the current snapshot. The current year may be incomplete.
All other statuses Currently recruiting
Current registered trial statusesEach percentage uses all published trials as its denominator.
COMPLETED75,532 (56%)
UNKNOWN19,179 (14.2%)
RECRUITING14,440 (10.7%)
TERMINATED8,828 (6.5%)
NOT YET RECRUITING5,764 (4.3%)
ACTIVE NOT RECRUITING5,665 (4.2%)
WITHDRAWN3,800 (2.8%)
ENROLLING BY INVITATION1,073 (0.8%)
SUSPENDED406 (0.3%)
Countries with published trial-site linksDistinct trials per country; multi-country studies can appear in several bars.
United States51,150
China11,851
France9,253
Canada8,744
United Kingdom7,735
Germany7,658
Spain6,816
Italy6,495
South Korea4,441
Netherlands4,006

How much of the source data is linked to standardized concepts?

Drug intervention rows mapped to RxNorm40,758 / 111,416 (36.6%)
Condition rows mapped to MONDO127,362 / 269,582 (47.2%)

Unmapped source rows remain visible as raw registry terms. A missing mapping is a data-linkage gap, not evidence that a study lacks an intervention or condition. These percentages describe source rows, not distinct trials.

What these comparisons show

The recruiting share measures the fraction of studies in this published data snapshot that currently report recruiting status. It does not predict enrollment availability at a particular site; confirm study contacts and eligibility directly with the registry. A trial can contain several condition and intervention rows, so the mapping percentages above use source rows, not distinct trials.

An unmapped intervention is retained as the registry supplied it. Low mapping coverage therefore means CureCurrent cannot confidently assign an RxNorm or MONDO identity to every source label; it does not mean the study lacks a drug or condition. The top disease and sponsor lists below count distinct trial IDs for each label or normalized disease, not number of patients, sites or therapeutic successes.

Reported trial statuses

  1. COMPLETED — 75,532 studies
  2. UNKNOWN — 19,179 studies
  3. RECRUITING — 14,440 studies
  4. TERMINATED — 8,828 studies
  5. NOT YET RECRUITING — 5,764 studies
  6. ACTIVE NOT RECRUITING — 5,665 studies
  7. WITHDRAWN — 3,800 studies
  8. ENROLLING BY INVITATION — 1,073 studies
  9. SUSPENDED — 406 studies
  10. NO LONGER AVAILABLE — 102 studies
  11. APPROVED FOR MARKETING — 49 studies
  12. AVAILABLE — 40 studies

Mapped diseases appearing in trials

  1. breast cancer — 8,988 studies
  2. type 2 diabetes mellitus — 8,175 studies
  3. obesity disorder — 7,627 studies
  4. diabetes mellitus — 5,397 studies
  5. prostate cancer — 4,513 studies
  6. heart failure — 3,869 studies
  7. chronic obstructive pulmonary disease — 3,823 studies
  8. Parkinson disease — 3,727 studies
  9. asthma — 3,671 studies
  10. lung cancer — 3,160 studies
  11. non-small cell lung carcinoma — 3,006 studies
  12. schizophrenia — 2,953 studies

Organizations leading registered studies

  1. AstraZeneca — 1,869 studies
  2. National Institute of Allergy and Infectious Diseases (NIAID) — 1,251 studies
  3. GlaxoSmithKline — 1,082 studies
  4. Novo Nordisk A/S — 1,068 studies
  5. Novartis Pharmaceuticals — 1,011 studies
  6. National Cancer Institute (NCI) — 953 studies
  7. Pfizer — 928 studies
  8. Eli Lilly and Company — 894 studies
  9. Boehringer Ingelheim — 868 studies
  10. Hoffmann-La Roche — 830 studies
  11. Merck Sharp & Dohme LLC — 818 studies
  12. Mayo Clinic — 734 studies

Snapshot provenance and limitations

Latest published sync: 2026-10-31 15:13:01.908903. Latest trial registry update date found in this projection: 2026-10-07 00:00:00.000000. The publication timestamp and the registry's source update date are not equivalent; both are displayed because a local sync may occur after a study's last official change.

This is a computed analysis of CureCurrent's currently published records, not a new clinical evidence review. Source identity: ClinicalTrials.gov for studies, MONDO for mapped diseases, and RxNorm for drug concepts. Read our methodology or inspect current data-quality indicators to understand what remains incomplete.